He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
ImmunoBrain Checkpoint, a clinical stage biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, today announced the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as its President and Chief Executive Officer.
Dr. Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech companies. He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom. Sanjay was Senior Vice President of R&D at Hoffman La Roche, and Vice President of Exploratory and Clinical Translational Research at Bristol-Myers Squibb, where he was responsible for multiple therapeutic areas including Immunology, Neuroscience, Rare Diseases, Fibrosis and Virology. He has held CEO and CMO positions in biotech with experience of a successful Nasdaq IPO (Annexon), an acquisition (MiroBio by Gilead), venture fundraising (Series A, B, D rounds), and multiple industry partnerships.
Sanjay has been instrumental in the development of several approved medicines, including Risdiplam, Emgality, Faricimab, Cymbalta, Aimovig and Deucravacitnib. Sanjay completed his residency in Neurology and fellowships in Neuroimmunology and Neurophysiology at Johns Hopkins. He graduated in medicine at St. Bartholomew's Hospital (UK's oldest hospital founded in 1123) and holds a First Class honors BSc degree from St. Mary's Hospital, London in Pathology & Basic Medical Sciences (Immunology).
"As a physician-scientist and seasoned biotech executive, Dr. Keswani possesses both the business acumen and the R&D expertise required to serve as Chief Executive Officer of ImmunoBrain," stated Nathan Hevrony, Co-founder and Executive Chairman of ImmunoBrain. "We are confident that Dr. Keswani's passion for developing effective solutions for patients, as well as his successful track record of building high-performing teams across a diverse range of biopharma companies, will result in transformative growth at ImmunoBrain and improved treatment and outcomes for individuals living with neurological conditions."
Subscribe To Our Newsletter & Stay Updated